Clinical Trial Update: CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CAR T cell therapy targeting VEGFR2 in patients with metastatic cancer, terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Melanoma
• Renal Cancer

Drugs mentioned

• CAR T cell receptor immunotherapy targeting VEGFR2

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Cancer, Metastatic Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-07-22